Move to topTop

Terumo Europe delighted to share that a positive guidance has been published by NICE mentioning that Holmium-166 Selective Internal Radiation Therapy (SIRT) using QuiremSpheresTM microspheres is recommended as an option for treating HCC patients with child-Pugh grade A liver impairment, when conventional transarterial therapies are inappropriate.

The NICE evaluation committee decided that QuiremSpheresTM (Holmium-166 microspheres) is   a cost-effective treatment option for unresectable advanced HCC patients and will be reimbursed by the National Health Service in the United Kingdom and Wales based on the recent available evidence in HCC1,2.

This guidance is based on NICE's Cost-Comparison Appraisal. The committee was able to make this positive recommendation based on a thorough assessment by an External Assessment Group (Centre for Reviews and Dissemination and Centre for Health Economics, University of York), a representative of the British Association for the Study of the Liver (BASL) and HCC-UK, and consultations with clinical experts.   ​

Prof. Rohini Sharma (Imperial College hospital in London) is enthusiastic about this updated guidance for QuiremSpheresTM
SIRT provides a minimally invasive treatment option for patients with unresectable HCC. Holmium-166 SIRT is a new technology with potential benefits.  We are currently investigating the impact of Holmium-166 SIRT in the RHEPAIR clinical trial".  ​

NICE Guidance is accessible here.​

*1 Reference: Reinders MTM, van Erpecum KJ, Smits MLJ, Braat AJAT, Bruijne J, Bruijnen R, Sprengers D, Man RA, Vegt E, IJzermans JNM, Moelker A, Lam MGEH. Safety and Efficacy of 166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. J Nucl Med. 2022 Dec;63(12):1891-1898. doi: 10.2967/jnumed.122.263823. Epub 2022 May 19. PMID: 35589409; PMCID: PMC9730925.
*2 Reference: Drescher R, Köhler A, Seifert P, Aschenbach R, Ernst T, Rauchfuß F, Freesmeyer M. Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer. Biomedicines. 2023 Jun 26;11(7):1831. doi: 10.3390/biomedicines11071831. PMID: 37509471; PMCID: PMC10377213.
*3 Reference: Schulze-Zachau V, Verset G, De Bondt P, De Keukeleire K, Gühne F, Heuschkel M, Hoffmann R-T, Bozzi E, Sciuto R, Lam MGEH, Deportós Moreno J, Debrus R, Zech CJ. Safety and efficacy of Holmium-166 selective internal radiotherapy of primary and secondary liver cancer confirmed by real-world data, Frontiers in Oncology 2024, June 11, Volume 14, 10.3389/fonc.2024.1404621.​

About Terumo Europe

Terumo Europe N.V. is a core player in the EMEA healthcare market by providing best-in-class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets, and sells a vast range of medical devices in five main business units: Interventional Systems, Pharmaceutical Solutions, Hospital Care Solutions, Cardiovascular and Life Care Solutions. Terumo Europe EMEA headquarters and production facilities are located in Leuven (Belgium), European Distribution Center in Genk (Belgium) and sales offices across EMEA.

Please visit for more information.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.